Saag KG, et al. - Researchers studied 1790 cases with a history of gout (urate crystal-induced arthritis) and normal/impaired (mild-to-severe) renal function to evaluate the effectiveness and safety of febuxostat extended release (XR) and immediate release (IR) in a 3-month, phase III, multicenter, double-blind, placebo-controlled study. They observed similar efficacy in both the formulations of febuxostat (XR and IR) with good tolerance in subjects with gout and normal/impaired renal function, including individuals with severe renal impairment.